Genmab 3Q Sales of Leukemia Drug Arzerra At GBP13.8 Million
October 22 2014 - 07:51AM
Dow Jones News
By Dominic Chopping
STOCKHOLM--Danish pharmaceutical company Genmab A/S (GEN.KO)
said Wednesday that net sales of leukemia drug Arzerra (ofatumumab)
during the third quarter of 2014 were GBP13.8 million.
This figure consists of net sales in the US of GBP5.3 million
and in the rest of the world of GBP8.5 million.
Under the terms of the collaboration with GlaxoSmithKline (GSK),
Genmab expects to receive a royalty payment of approximately DKK27
million.
The rest of world sales for the third quarter were enhanced by
sales related to the supply of ofatumumab for clinical trials run
by other companies.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter:
@WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024